BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 19489856)

  • 1. Erythema multiforme induced by sorafenib.
    Feltes RA; Feito Rodríguez M; González-Beato MJ
    Clin Exp Dermatol; 2009 Oct; 34(7):e368-9. PubMed ID: 19489856
    [No Abstract]   [Full Text] [Related]  

  • 2. Sorafenib-induced erythema multiforme in metastatic renal cell carcinoma.
    Bilaç C; Müezzinoğlu T; Ermertcan AT; Kayhan TC; Temeltaş G; Oztürkcan S; Temiz P
    Cutan Ocul Toxicol; 2009; 28(2):90-2. PubMed ID: 19514932
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Non-pigmenting fixed drug eruption induced by sorafenib.
    Tanabe K; Amoh Y; Mii S; Eto H; Iwamura M; Katsuoka K
    Acta Derm Venereol; 2010 May; 90(3):307. PubMed ID: 20526556
    [No Abstract]   [Full Text] [Related]  

  • 4. Erythema multiforme induced by sorafenib for metastatic renal cell carcinoma.
    Ikeda M; Fujita T; Mii S; Tanabe K; Tabata K; Matsumoto K; Satoh T; Iwamura M
    Jpn J Clin Oncol; 2012 Sep; 42(9):820-4. PubMed ID: 22782962
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sorafenib-induced erythema multiforme: three cases.
    Namba M; Tsunemi Y; Kawashima M
    Eur J Dermatol; 2011; 21(6):1015-6. PubMed ID: 21926043
    [No Abstract]   [Full Text] [Related]  

  • 6. Hand-foot and stump syndrome to sorafenib.
    Lai SE; Kuzel T; Lacouture ME
    J Clin Oncol; 2007 Jan; 25(3):341-3. PubMed ID: 17235051
    [No Abstract]   [Full Text] [Related]  

  • 7. Sorafenib-induced erythema multiforme for metastatic renal cell carcinoma.
    Kodaira M; Takahashi S; Takeuchi K; Yuasa T; Saotome T; Yonese J; Fukui I; Hatake K
    Ann Oncol; 2010 Jul; 21(7):1563-1565. PubMed ID: 20573851
    [No Abstract]   [Full Text] [Related]  

  • 8. Chloracne-like drug eruption associated with sorafenib.
    Pickert A; Hughes M; Wells M
    J Drugs Dermatol; 2011 Nov; 10(11):1331-4. PubMed ID: 22052319
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Localized palmar-plantar epidermal hyperplasia: a previously undefined dermatologic toxicity to sorafenib.
    Beldner M; Jacobson M; Burges GE; Dewaay D; Maize JC; Chaudhary UB
    Oncologist; 2007 Oct; 12(10):1178-82. PubMed ID: 17962611
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sorafenib: atypical cutaneous side effects.
    Richetta AG; Maiani E; Carboni V; Carlomagno V; Cimillo M; Mattozzi C; Calvieri S
    Eur J Dermatol; 2007; 17(6):549-50. PubMed ID: 17951148
    [No Abstract]   [Full Text] [Related]  

  • 11. Prospective study of the cutaneous adverse effects of sorafenib, a novel multikinase inhibitor.
    Autier J; Escudier B; Wechsler J; Spatz A; Robert C
    Arch Dermatol; 2008 Jul; 144(7):886-92. PubMed ID: 18645140
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Application monitoring of the use of sorafenib in papillary renal cell carcinoma].
    Schrader AJ; Hegele A; Olbert P; Buer J; Jeron A; Hofmann R
    Urologe A; 2007 Sep; 46(9):1291. PubMed ID: 17668165
    [No Abstract]   [Full Text] [Related]  

  • 13. Transient perforating folliculitis induced by sorafenib.
    Minami-Hori M; Ishida-Yamamoto A; Komatsu S; Iiduka H
    J Dermatol; 2010 Sep; 37(9):833-4. PubMed ID: 20883372
    [No Abstract]   [Full Text] [Related]  

  • 14. Cutaneous drug eruptions induced by sorafenib: a case series.
    Maddox JS; Kung EF; Petronic-Rosic V; Sethi A
    J Drugs Dermatol; 2008 Sep; 7(9):891-3. PubMed ID: 19112807
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sorafenib and surgical complications: a case report of adverse reaction to sorafenib during treatment for renal cell carcinoma.
    Eng FC; Easson AM; Szentgyorgyi E; Knox JJ
    Eur J Surg Oncol; 2009 Feb; 35(2):219-21. PubMed ID: 17976949
    [No Abstract]   [Full Text] [Related]  

  • 16. Long-term safety of sorafenib in advanced renal cell carcinoma: follow-up of patients from phase III TARGET.
    Hutson TE; Bellmunt J; Porta C; Szczylik C; Staehler M; Nadel A; Anderson S; Bukowski R; Eisen T; Escudier B;
    Eur J Cancer; 2010 Sep; 46(13):2432-40. PubMed ID: 20656473
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sorafenib-induced erythema multiforme.
    MacGregor JL; Silvers DN; Grossman ME; Sherman WH
    J Am Acad Dermatol; 2007 Mar; 56(3):527-8. PubMed ID: 17241689
    [No Abstract]   [Full Text] [Related]  

  • 18. Sorafenib-induced palmoplantar hyperkeratosis.
    Lountzis NI; Maroon MS
    J Drugs Dermatol; 2008 Jun; 7(6):588-9. PubMed ID: 18561593
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Erythema multiforme-like drug reaction to sorafenib.
    Lewin J; Farley-Loftus R; Pomeranz MK
    J Drugs Dermatol; 2011 Dec; 10(12):1462-3. PubMed ID: 22134572
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The histologic spectrum of epithelial neoplasms induced by sorafenib.
    Kwon EJ; Kish LS; Jaworsky C
    J Am Acad Dermatol; 2009 Sep; 61(3):522-7. PubMed ID: 19700018
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.